Let This Be Our New Year's Pledge

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2017 Jan 28

PMID 28126914

Citations 1

Authors

Bruce A Chabner

Martin J Murphy

Affiliations

Soon will be listed here.

Citing Articles

Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review.

Lo Greco M, Marano G, La Rocca M, Acquaviva G, Milazzotto R, Liardo R Cancers (Basel). 2025; 17(3).

PMID: 39941789 PMC: 11815860. DOI: 10.3390/cancers17030420.

Efficacy of Panobinostat for the Treatment of Multiple Myeloma.

Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Gavriatopoulou M, Terpos E, Dimopoulos M J Oncol. 2020; 2020:7131802.

PMID: 32411240 PMC: 7201625. DOI: 10.1155/2020/7131802.

References

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

Goldberg R . In Memoriam: A Tribute to Daniel J. Sargent, Ph.D. Oncologist. 2016; 21(12):1540-1541. PMC: 5153349. DOI: 10.1634/theoncologist.2016-0425. View

Choueiri T, Escudier B, Powles T, Mainwaring P, Rini B, Donskov F . Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1814-23. PMC: 5024539. DOI: 10.1056/NEJMoa1510016. View

Khalil D, Smith E, Brentjens R, Wolchok J . The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nat Rev Clin Oncol. 2016; 13(5):273-90. PMC: 5551685. DOI: 10.1038/nrclinonc.2016.25. View

Nghiem P, Bhatia S, Lipson E, Kudchadkar R, Miller N, Annamalai L . PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma. N Engl J Med. 2016; 374(26):2542-52. PMC: 4927341. DOI: 10.1056/NEJMoa1603702. View

Wilkerson J, Abdallah K, Hugh-Jones C, Curt G, Rothenberg M, Simantov R . Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis. Lancet Oncol. 2016; 18(1):143-154. DOI: 10.1016/S1470-2045(16)30633-7. View

Guinney J, Wang T, Laajala T, Kanigel Winner K, Bare J, Chaibub Neto E . Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. Lancet Oncol. 2016; 18(1):132-142. PMC: 5217180. DOI: 10.1016/S1470-2045(16)30560-5. View

McLornan D, List A, Mufti G . Applying synthetic lethality for the selective targeting of cancer. N Engl J Med. 2014; 371(18):1725-35. DOI: 10.1056/NEJMra1407390. View

Kaufman H, Russell J, Hamid O, Bhatia S, Terheyden P, DAngelo S . Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016; 17(10):1374-1385. PMC: 5587154. DOI: 10.1016/S1470-2045(16)30364-3. View

10.

Turner N, Ro J, Andre F, Loi S, Verma S, Iwata H . Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015; 373(3):209-19. DOI: 10.1056/NEJMoa1505270. View